pharma · Hypertension · Uncontrolled and Resistant Hypertension · MLYS
Mineralys Therapeutics
Mineralys Therapeutics is a pharma organization headquartered in Radnor, USA. It trades on NYSE under ticker MLYS. Primary therapeutic focus areas include Hypertension, Uncontrolled and Resistant Hypertension, Chronic Ki
Radnor, USA HQ
2020 Founded
106 Employees
Public company Type
MLYS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Radnor, USA
- Founded
- 2020
- Employees
- 106
- Programs
- 7
- Drugs
- 6
- Patents
- 0
MLS-101-206
Phase 2 · small molecule · Chronic Kidney Disease
MLS-101-206 for Chronic Kidney Disease is a Phase 2 program (small_molecule) at Mineralys Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code MLS-101-206
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Mineralys Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Chronic Kidney Disease
- Status
- completed
- Trials
- 1